TY - JOUR AB - Chronic hypoxia is one of the most common causes of secondary pulmonary hypertension, the mechanisms of which remain unclear. MicroRNAs (miRNAs) are small, noncoding RNAs that inhibit the translation or accelerate the degradation of mRNA. Previous studies have demonstrated that deregulated miRNA expression contributes to various cellular processes including cell apoptosis and proliferation, which are mediated by hypoxia. In the present study, the expression of miR‑98 was identified to be decreased in the lung tissue of a hypoxic pulmonary hypertension (HPH) rat model and pulmonary artery (PA) smooth muscle cells (PASMCs), which was induced by hypoxia. By transfecting miR‑98 mimics into PASMCs, the high expression of miR‑98 inhibited cell proliferation, but upregulated hypoxia‑induced PASMCs apoptosis. However, these effects of miR‑98 mimics on PASMCs were reversed by ALK1 (activin receptor‑like kinase‑1) overexpression. ALK1 was identified as a candidate target of miR‑98. In addition, overexpressing miR‑98 markedly decreased the pulmonary artery wall thickness and the right ventricular systolic pressure in rats induced by hypoxia. These results provided clear evidence that miR‑98 was a direct regulator of ALK1, and that the downregulation of miR‑98 contributed to the pathogenesis of HPH. These results provide a novel potential therapeutic strategy for the treatment of HPH. AD - Department of Respiratory Medicine, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China AU - Li,Qingling AU - Zhou,Xincan AU - Zhou,Xianghui DA - 2019/09/01 DO - 10.3892/mmr.2019.10482 EP - 2176 IS - 3 JO - Mol Med Rep KW - pulmonary hypertension microRNA‑98 activin receptor‑like kinase‑1 hypoxia PY - 2019 SN - 1791-2997 1791-3004 SP - 2167 ST - Downregulation of miR‑98 contributes to hypoxic pulmonary hypertension by targeting ALK1 T2 - Molecular Medicine Reports TI - Downregulation of miR‑98 contributes to hypoxic pulmonary hypertension by targeting ALK1 UR - https://doi.org/10.3892/mmr.2019.10482 VL - 20 ER -